BACKGROUND: Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD). METHODS: Beginning in March 2015, we conducted a randomized, controlled trial of ZMapp plus the current standard of care as compared with the current standard of care alone in patients with EVD that was diagnosed in West Africa by polymerase-chain-reaction (PCR) assay. Eligible patients of any age were randomly assigned in a 1:1 ratio to receive either the current standard of care or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day). Patients were stratified according to baseline PCR cycle-threshold value for the virus (≤22 vs. >22) and country of enrollment. Oral favipiravir was part of the current standard of care in Guinea. The primary end point was mortality at 28 days. RESULTS: A total of 72 patients were enrolled at sites in Liberia, Sierra Leone, Guinea, and the United States. Of the 71 patients who could be evaluated, 21 died, representing an overall case fatality rate of 30%. Death occurred in 13 of 35 patients (37%) who received the current standard of care alone and in 8 of 36 patients (22%) who received the current standard of care plus ZMapp. The observed posterior probability that ZMapp plus the current standard of care was superior to the current standard of care alone was 91.2%, falling short of the prespecified threshold of 97.5%. Frequentist analyses yielded similar results (absolute difference in mortality with ZMapp, -15 percentage points; 95% confidence interval, -36 to 7). Baseline viral load was strongly predictive of both mortality and duration of hospitalization in all age groups. CONCLUSIONS: In this randomized, controlled trial of a putative therapeutic agent for EVD, although the estimated effect of ZMapp appeared to be beneficial, the result did not meet the prespecified statistical threshold for efficacy. (Funded by the National Institute of Allergy and Infectious Diseases and others; PREVAIL II ClinicalTrials.gov number, NCT02363322 .).
RCT Entities:
BACKGROUND: Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD). METHODS: Beginning in March 2015, we conducted a randomized, controlled trial of ZMapp plus the current standard of care as compared with the current standard of care alone in patients with EVD that was diagnosed in West Africa by polymerase-chain-reaction (PCR) assay. Eligible patients of any age were randomly assigned in a 1:1 ratio to receive either the current standard of care or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day). Patients were stratified according to baseline PCR cycle-threshold value for the virus (≤22 vs. >22) and country of enrollment. Oral favipiravir was part of the current standard of care in Guinea. The primary end point was mortality at 28 days. RESULTS: A total of 72 patients were enrolled at sites in Liberia, Sierra Leone, Guinea, and the United States. Of the 71 patients who could be evaluated, 21 died, representing an overall case fatality rate of 30%. Death occurred in 13 of 35 patients (37%) who received the current standard of care alone and in 8 of 36 patients (22%) who received the current standard of care plus ZMapp. The observed posterior probability that ZMapp plus the current standard of care was superior to the current standard of care alone was 91.2%, falling short of the prespecified threshold of 97.5%. Frequentist analyses yielded similar results (absolute difference in mortality with ZMapp, -15 percentage points; 95% confidence interval, -36 to 7). Baseline viral load was strongly predictive of both mortality and duration of hospitalization in all age groups. CONCLUSIONS: In this randomized, controlled trial of a putative therapeutic agent for EVD, although the estimated effect of ZMapp appeared to be beneficial, the result did not meet the prespecified statistical threshold for efficacy. (Funded by the National Institute of Allergy and Infectious Diseases and others; PREVAIL II ClinicalTrials.gov number, NCT02363322 .).
Authors: Yazdan Yazdanpanah; Peter Horby; Johan van Griensven; France Mentre; Vinh-Kim Nguyen; Jean Marie Denis Malvy; Jake Dunning; Daouda Sissoko; Jean-Francois Delfraissy; Yves Levy Journal: Lancet Infect Dis Date: 2015-11 Impact factor: 25.071
Authors: Peter B Jahrling; Lisa E Hensley; Kevin Barrett; Henry Clifford Lane; Richard T Davey Journal: J Infect Dis Date: 2015-05-09 Impact factor: 5.226
Authors: Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger Journal: Nature Date: 2014-08-29 Impact factor: 49.962
Authors: Samuel J Crowe; Matthew J Maenner; Solomon Kuah; Bobbie Rae Erickson; Megan Coffee; Barbara Knust; John Klena; Joyce Foday; Darren Hertz; Veerle Hermans; Jay Achar; Grazia M Caleo; Michel Van Herp; César G Albariño; Brian Amman; Alison Jane Basile; Scott Bearden; Jessica A Belser; Eric Bergeron; Dianna Blau; Aaron C Brault; Shelley Campbell; Mike Flint; Aridth Gibbons; Christin Goodman; Laura McMullan; Christopher Paddock; Brandy Russell; Johanna S Salzer; Angela Sanchez; Tara Sealy; David Wang; Gbessay Saffa; Alhajie Turay; Stuart T Nichol; Jonathan S Towner Journal: Emerg Infect Dis Date: 2016-02 Impact factor: 6.883
Authors: Travis K Warren; Jay Wells; Rekha G Panchal; Kelly S Stuthman; Nicole L Garza; Sean A Van Tongeren; Lian Dong; Cary J Retterer; Brett P Eaton; Gianluca Pegoraro; Shelley Honnold; Shanta Bantia; Pravin Kotian; Xilin Chen; Brian R Taubenheim; Lisa S Welch; Dena M Minning; Yarlagadda S Babu; William P Sheridan; Sina Bavari Journal: Nature Date: 2014-03-02 Impact factor: 49.962
Authors: Adam R Aluisio; Shiromi M Perera; Derrick Yam; Stephanie Garbern; Jillian L Peters; Logan Abel; Daniel K Cho; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Suzanne Brinkmann; Lindsey Locks; Tao Liu; Adam C Levine Journal: J Nutr Date: 2019-10-01 Impact factor: 4.798
Authors: Anna Z Wec; Zachary A Bornholdt; Shihua He; Andrew S Herbert; Eileen Goodwin; Ariel S Wirchnianski; Bronwyn M Gunn; Zirui Zhang; Wenjun Zhu; Guodong Liu; Dafna M Abelson; Crystal L Moyer; Rohit K Jangra; Rebekah M James; Russell R Bakken; Natasha Bohorova; Ognian Bohorov; Do H Kim; Michael H Pauly; Jesus Velasco; Robert H Bortz; Kevin J Whaley; Tracey Goldstein; Simon J Anthony; Galit Alter; Laura M Walker; John M Dye; Larry Zeitlin; Xiangguo Qiu; Kartik Chandran Journal: Cell Host Microbe Date: 2019-01-09 Impact factor: 21.023
Authors: Mable Chan; Frederick W Holtsberg; Hong Vu; Katie A Howell; Anders Leung; Evelyn Van der Hart; Paul H Walz; M Javad Aman; Shantha Kodihalli; Darwyn Kobasa Journal: J Infect Dis Date: 2018-11-22 Impact factor: 5.226
Authors: Gai Liu; Peter J Nash; Britney Johnson; Colette Pietzsch; Ma Xenia G Ilagan; Alexander Bukreyev; Christopher F Basler; Terry L Bowlin; Donald T Moir; Daisy W Leung; Gaya K Amarasinghe Journal: ACS Infect Dis Date: 2017-02-09 Impact factor: 5.084
Authors: Jerry F Brown; John M Dye; Sam Tozay; Gertrude Jeh-Mulbah; David A Wohl; William A Fischer; Coleen K Cunningham; Kathleen Rowe; Peter Zacharias; James van Hasselt; David A Norwood; Nathan M Thielman; Samantha E Zak; David L Hoover Journal: J Infect Dis Date: 2018-07-13 Impact factor: 5.226
Authors: Anna Z Wec; Andrew S Herbert; Charles D Murin; Elisabeth K Nyakatura; Dafna M Abelson; J Maximilian Fels; Shihua He; Rebekah M James; Marc-Antoine de La Vega; Wenjun Zhu; Russell R Bakken; Eileen Goodwin; Hannah L Turner; Rohit K Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R Lai; Laura M Walker; Andrew B Ward; John M Dye; Kartik Chandran; Zachary A Bornholdt Journal: Cell Date: 2017-05-18 Impact factor: 41.582
Authors: Saori Sakabe; Brian M Sullivan; Jessica N Hartnett; Refugio Robles-Sikisaka; Karthik Gangavarapu; Beatrice Cubitt; Brian C Ware; Dylan Kotliar; Luis M Branco; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Donald S Grant; Robert F Garry; Kristian G Andersen; Juan Carlos de la Torre; Pardis C Sabeti; John S Schieffelin; Michael B A Oldstone Journal: Proc Natl Acad Sci U S A Date: 2018-07-23 Impact factor: 11.205
Authors: Adam R Aluisio; Derrick Yam; Jillian L Peters; Daniel K Cho; Shiromi M Perera; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Michael A Smit; Tao Liu; Adam C Levine Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079